12/20
02:03 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/16
10:55 am
clrb
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
Low
Report
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
12/11
12:54 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
12/10
05:00 pm
clrb
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
High
Report
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/5
09:05 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.
11/21
08:06 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
Low
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
11/21
08:00 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Low
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
11/19
08:37 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
11/18
11:00 am
clrb
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/18
07:05 am
clrb
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
High
Report
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
11/15
09:05 am
clrb
Cellectar Biosciences Q3 2024 Earnings Preview Nov. 15, 2024 9:03 AM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
Medium
Report
Cellectar Biosciences Q3 2024 Earnings Preview Nov. 15, 2024 9:03 AM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
11/14
08:08 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
Medium
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
11/14
08:05 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Medium
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
11/12
08:05 am
clrb
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Low
Report
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
11/11
04:05 pm
clrb
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Low
Report
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
11/7
06:44 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
11/7
06:40 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
11/1
05:00 pm
clrb
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Low
Report
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
10/11
03:01 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
9/26
02:11 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.